Switch to:
GuruFocus has detected 2 Warning Signs with Biomarin Pharmaceutical Inc $BMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Biomarin Pharmaceutical Inc (NAS:BMRN)
EV-to-EBITDA
-22.50 (As of Today)

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Biomarin Pharmaceutical Inc's enterprise value is $15,038 Mil. Biomarin Pharmaceutical Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Dec. 2016 was $-668 Mil. Therefore, Biomarin Pharmaceutical Inc's EV/EBITDA ratio for today is -22.50.

BMRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25504   Max: 1532.3
Current: -22.52

-25504
1532.3

During the past 13 years, the highest EV/EBITDA Ratio of Biomarin Pharmaceutical Inc was 1532.30. The lowest was -25504.00. And the median was -76.30.

BMRN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. BMRN: -22.52 )

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

As of today, Biomarin Pharmaceutical Inc's stock price is $95.84. Biomarin Pharmaceutical Inc's earnings per share for the trailing twelve months (TTM) ended in Dec. 2016 was $-3.84. Therefore, Biomarin Pharmaceutical Inc's P/E Ratio for today is .

The "classic" EV/EBITDA ratio is much better in capturing debt and net cash than the P/E Ratio.


Definition

Biomarin Pharmaceutical Inc's EV/EBITDA for today is calculated as:

EV/EBITDA=Enterprise Value (Today)/Earnings Before Depreciation and Amortization (TTM)
=15038.352/-668.477
=-22.50

Biomarin Pharmaceutical Inc's current Enterprise Value is $15,038 Mil.
Biomarin Pharmaceutical Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Dec. 2016 was -59.039 (Mar. 2016 ) + -518.587 (Jun. 2016 ) + -28.524 (Sep. 2016 ) + -62.327 (Dec. 2016 ) = $-668 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

EV/EBITDA (Enterprise value/EBITDA) is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the P/E Ratio to determine the fair market value of a company.

Biomarin Pharmaceutical Inc's P/E Ratio for today is calculated as:

P/E Ratio=Share Price (Today)/Earnings Per Share (TTM)
=95.84/-3.84
=

Biomarin Pharmaceutical Inc's share price for today is $95.84.
Biomarin Pharmaceutical Inc's Earnings Per Share for the trailing twelve months (TTM) ended in Dec. 2016 was -0.53 (Mar. 2016 ) + -2.61 (Jun. 2016 ) + -0.26 (Sep. 2016 ) + -0.44 (Dec. 2016 ) = $-3.84.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV/EBITDA outperforms companies measured as cheap by other ratios such as P/E Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Related Terms

Enterprise Value, Earnings Before Depreciation and Amortization, P/E Ratio


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Biomarin Pharmaceutical Inc Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
ev2ebitda -326.1726.4558.82180.64-23,974.95-94.71-81.24-400.47-266.35-21.15

Biomarin Pharmaceutical Inc Quarterly Data

Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16
ev2ebitda -207.79-400.47-293.18-186.62-82.42-266.35-198.70-24.22-31.62-21.15
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK